|
1
|
Oldenburg CS, Boll D, Nicolaije KA, Vos
MC, Pijnenborg JM, Coebergh JW, Beijer S, van de Poll-Franse LV and
Ezendam NP: The relationship of body mass index with quality of
life among endometrial cancer survivors: A study from the
population-based PROFILES registry. Gynecol Oncol. 129:216–221.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lachance JA, Darus CJ and Rice LW:
Surgical management and postoperative treatment of endometrial
carcinoma. Rev Obstet Gynecol. 1:97–105. 2008.PubMed/NCBI
|
|
3
|
Singh M, Spoelstra NS, Jean A, Howe E,
Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus
RR, et al: ZEB1 expression in type I vs type II endometrial
cancers: A marker of aggressive disease. Mod Pathol. 21:912–923.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Havrilesky LJ, Secord AA, Bae-Jump V,
Ayeni T, Calingaert B, Clarke-Pearson DL, Berchuck A and Gehrig PA:
Outcomes in surgical stage I uterine papillary serous carcinoma.
Gynecol Oncol. 105:677–682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stefansson IM, Salvesen HB, Immervoll H
and Akslen LA: Prognostic impact of histological grade and vascular
invasion compared with tumour cell proliferation in endometrial
carcinoma of endometrioid type. Histopathology. 44:472–479. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lax SF, Kurman RJ, Pizer ES, Wu L and
Ronnett BM: A binary architectural grading system for uterine
endometrial endometrioid carcinoma has superior reproducibility
compared with FIGO grading and identifies subsets of advance-stage
tumors with favorable and unfavorable prognosis. Am J Surg Pathol.
24:1201–1208. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Amant F, Moerman P, Neven P, Timmerman D,
Van Limbergen E and Vergote I: Endometrial cancer. Lancet.
366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Trimbos JB, Vergote I, Bolis G, Vermorken
JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone
G, et al; EORTC-ACTION collaborators. European Organisation for
Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian
Neoplasm: Impact of adjuvant chemotherapy and surgical staging in
early-stage ovarian carcinoma: European Organisation for Research
and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm
trial. J Natl Cancer Inst. 95:113–125. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kelly MG, O’malley DM, Hui P, McAlpine J,
Yu H, Rutherford TJ, Azodi M and Schwartz PE: Improved survival in
surgical stage I patients with uterine papillary serous carcinoma
(UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol
Oncol. 98:353–359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jutzi L, Hoskins P, Lim P, Aquino-Parsons
C, Tinker A and Kwon JS: The importance of adjuvant chemotherapy
and pelvic radiotherapy in high-risk early stage endometrial
carcinoma. Gynecol Oncol. 131:581–585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Soumarová R, Homola L, Perková H, Czudek
S, Skrovina M and Adamcík L: The role of interstitial brachytherapy
in multimodality management of solid tumors. Rozhl Chir.
86:533–539. 2007.(In Czech).
|
|
12
|
Yi BR, OSN, Kang NH, Hwang KA, Kim SU,
Jeung EB, Kim YB, Heo GJ and Choi KC: Genetically engineered stem
cells expressing cytosine deaminase and interferon-β migrate to
human lung cancer cells and have potentially therapeutic anti-tumor
effects. Int J Oncol. 39:833–839. 2011.PubMed/NCBI
|
|
13
|
Yi BR, Park MA, Lee HR, Kang NH, Choi KJ,
Kim SU and Choi KC: Suppression of the growth of human colorectal
cancer cells by therapeutic stem cells expressing cytosine
deaminase and interferon-β via their tumor-tropic effect in
cellular and xenograft mouse models. Mol Oncol. 7:543–554. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Seol HJ, Jin J, Seong DH, Joo KM, Kang W,
Yang H, Kim J, Shin CS, Kim Y, Kim KH, et al: Genetically
engineered human neural stem cells with rabbit carboxyl esterase
can target brain metastasis from breast cancer. Cancer Lett.
311:152–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim KY, Yi BR, Lee HR, Kang NH, Jeung EB,
Kim SU and Choi KC: Stem cells with fused gene expression of
cytosine deaminase and interferon-β migrate to human gastric cancer
cells and result in synergistic growth inhibition for potential
therapeutic use. Int J Oncol. 40:1097–1104. 2012.
|
|
16
|
Kim KY, Kim SU, Leung PC, Jeung EB and
Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on
ovarian cancer cells using genetically engineered stem cells:
Tumor-tropic potential and inhibition of ovarian cancer cell
growth. Cancer Sci. 101:955–962. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yi BR, Hwang KA, Kang NH, Kim SU, Jeung
EB, Kim HC and Choi KC: Synergistic effects of genetically
engineered stem cells expressing cytosine deaminase and
interferon-β via their tumor tropism to selectively target human
hepatocarcinoma cells. Cancer Gene Ther. 19:644–651. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yi BR, Choi KJ, Kim SU and Choi KC:
Therapeutic potential of stem cells expressing suicide genes that
selectively target human breast cancer cells: Evidence that they
exert tumoricidal effects via tumor tropism (Review). Int J Oncol.
41:798–804. 2012.PubMed/NCBI
|
|
19
|
Yi BR, Kim SU and Choi KC: Development and
application of neural stem cells for treating various human
neurological diseases in animal models. Lab Anim Res. 29:131–137.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trinchieri G: Type I interferon: Friend or
foe? J Exp Med. 207:2053–2063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yi BR, Hwang KA, Aboody KS, Jeung EB, Kim
SU and Choi KC: Selective antitumor effect of neural stem cells
expressing cytosine deaminase and interferon-beta against ductal
breast cancer cells in cellular and xenograft models. Stem Cell Res
(Amst). 12:36–48. 2014. View Article : Google Scholar
|
|
22
|
Guo B, Chang EY and Cheng G: The type I
IFN induction pathway constrains Th17-mediated autoimmune
inflammation in mice. J Clin Invest. 118:1680–1690. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Monroe KM, McWhirter SM and Vance RE:
Induction of type I interferons by bacteria. Cell Microbiol.
12:881–890. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sangfelt O and Strander H: Apoptosis and
cell growth inhibition as antitumor effector functions of
interferons. Med Oncol. 18:3–14. 2001. View Article : Google Scholar
|
|
25
|
Damdinsuren B, Nagano H, Wada H, Noda T,
Natsag J, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, et
al: Interferon alpha receptors are important for antiproliferative
effect of interferon-alpha against human hepatocellular carcinoma
cells. Hepatol Res. 37:77–83. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Olawaiye AB and Boruta DM II: Management
of women with clear cell endometrial cancer: A Society of
Gynecologic Oncology (SGO) review. Gynecol Oncol. 113:277–283.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Morris L, Stevens MJ, Valmadre S, Martland
J and Lee T: Adjuvant intravaginal brachytherapy for uterus
didelphys with synchronous endometrial adenocarcinomas and
unfavourable vaginal topography. Gynecol Oncol Case Rep. 2:121–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nout RA, Putter H, Jürgenliemk-Schulz IM,
Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A,
Stenfert Kroese MC, Nijman HW, et al: Five-year quality of life of
endometrial cancer patients treated in the randomised Post
Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial
and comparison with norm data. Eur J Cancer. 48:1638–1648. 2012.
View Article : Google Scholar
|
|
29
|
Hagiwara S, Kudo M, Nakatani T, Sakaguchi
Y, Nagashima M, Fukuta N, Kimura M, Hayakawa S and Munakata H:
Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2
tumour cell growth in nude mice by apoptosis of p53. Br J Cancer.
97:1532–1537. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wada H, Nagano H, Yamamoto H, Arai I, Ota
H, Nakamura M, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, et
al: Combination therapy of interferon-alpha and 5-fluorouracil
inhibits tumor angiogenesis in human hepatocellular carcinoma cells
by regulating vascular endothelial growth factor and angiopoietins.
Oncol Rep. 18:801–809. 2007.PubMed/NCBI
|
|
31
|
Kondo M, Nagano H, Wada H, Damdinsuren B,
Yamamoto H, Hiraoka N, Eguchi H, Miyamoto A, Yamamoto T, Ota H, et
al: Combination of IFN-alpha and 5-fluorouracil induces apoptosis
through IFN-alpha/beta receptor in human hepatocellular carcinoma
cells. Clin Cancer Res. 11:1277–1286. 2005.PubMed/NCBI
|
|
32
|
Kim DJ, Yi BR, Lee HR, Kim SU and Choi KC:
Pancreatic tumor mass in a xenograft mouse model is decreased by
treatment with therapeutic stem cells following introduction of
therapeutic genes. Oncol Rep. 30:1129–1136. 2013.PubMed/NCBI
|
|
33
|
Kang NH, Hwang KA, Yi BR, Lee HJ, Jeung
EB, Kim SU and Choi KC: Human amniotic fluid-derived stem cells
expressing cytosine deaminase and thymidine kinase inhibits the
growth of breast cancer cells in cellular and xenograft mouse
models. Cancer Gene Ther. 19:412–419. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aboody KS, Brown A, Rainov NG, Bower KA,
Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al:
Neural stem cells display extensive tropism for pathology in adult
brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA.
97:12846–12851. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Heese O, Disko A, Zirkel D, Westphal M and
Lamszus K: Neural stem cell migration toward gliomas in vitro.
Neuro Oncol. 7:476–484. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yi BR, Hwang KA, Kim YB, Kim SU and Choi
KC: Effects of genetically engineered stem cells expressing
cytosine deaminase and interferon-beta or carboxyl esterase on the
growth of LNCaP rrostate cancer cells. Int J Mol Sci.
13:12519–12532. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pitchford SC, Furze RC, Jones CP, Wengner
AM and Rankin SM: Differential mobilization of subsets of
progenitor cells from the bone marrow. Cell Stem Cell. 4:62–72.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Simons M and Ware JA: Therapeutic
angiogenesis in cardiovascular disease. Nat Rev Drug Discov.
2:863–871. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang J, Wang J, Kong X, Yang J, Guo L,
Zheng F, Zhang L, Huang Y and Wan Y: Vascular endothelial growth
factor promotes cardiac stem cell migration via the PI3K/Akt
pathway. Exp Cell Res. 315:3521–3531. 2009. View Article : Google Scholar : PubMed/NCBI
|
